{
    "nctId": "NCT00967031",
    "briefTitle": "Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain Metastases",
    "officialTitle": "A Multicenter Phase II Clinical Trial Assessing the Efficacy of the Combination of Lapatinib and Capecitabine in Patients With Non Pretreated Brain Metastasis From HER2 Positive Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Metastatic Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 45,
    "primaryOutcomeMeasure": "Objective response rate",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed invasive breast cancer\n\n  * Stage IV disease\n* At least 1 measurable CNS lesion \u2265 10 mm on T1-weighted gadolinium-enhanced MRI\n\n  * No single brain metastasis that could be treated by surgery\n* HER-2 positive primary tumor as defined as IHC3+ or IHC2+ and FISH-positive\n* Hormone receptor status: not specified\n\nPATIENT CHARACTERISTICS:\n\n* Menopausal status not specified\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Life expectancy \u2265 3 months\n* Absolute Neutrophil Count (ANC) \u2265 1,000/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n* Hemoglobin \u2265 10g/dL\n* Creatinine \u2265 1.5 times upper limit of normal (ULN)\n* Albumin \u2265 2.5 g/dL\n* Serum bilirubin \u2264 1.5 times ULN (unless due to Gilbert's syndrome)\n* ASAT and ALAT \u2264 3 times ULN (\u2264 5 times ULN with documented liver metastasis)\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception 2 weeks before, during, and for 28 days after completion of study treatment (female) or for 1 week after completion of treatment (male)\n* Able to swallow and retain oral medication\n* Affiliated to a Social Security System\n* No known contraindication to MRI\n* No prior or active malignancy, unless disease free for \u2265 10 years\n* No other concurrent severe and/or uncontrolled medical disease which could compromise study participation, including any of the following:\n\n  * Infection\n  * Cardiac disease (e.g., uncontrolled hypertension, congestive cardiac failure, ventricular arrhythmias, active ischemic heart disease, myocardial infarction within the past year, Left Ventricular EJection Fraction (LVEF) \\> grade 2)\n  * Current active hepatic or biliary disease (except for Gilbert syndrome, asymptomatic gallstones, liver metastasis or stable chronic liver disease per investigator assessment)\n  * Renal disease\n  * Active gastrointestinal (GI) tract ulceration, malabsorption syndrome, active uncontrolled ulcerative colitis, or disease significantly affecting GI function\n  * Severely impaired lung function (e.g., spirometry and diffusion capacity of lung for carbon monoxide (DLCO) \u2264 50% of normal, and O_2 saturation \u2264 88% at rest on room air)\n* No known dihydropyrimidine dehydrogenase deficiency\n* No significantly altered mental status prohibiting the understanding of the study, or with psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule\n* Not deprived of liberty or placed under the authority of a tutor\n\nPRIOR CONCURRENT THERAPY:\n\n* At least 2 weeks since prior breast cancer treatment (e.g., trastuzumab, chemotherapy, immunotherapy or biological response modifiers, endocrine therapy, or radiotherapy)\n* More than 30 days since prior investigational drugs\n* More than 14 days since prior and no concurrent strong inhibitors or inducers of the cytochrome P450 isoenzyme 3A4 (CYP3A4) (i.e., clarithromycin, ketoconazole, itraconazole, voriconazole, ritonavir)\n* No prior whole brain radiotherapy (WBRT) or brain stereotactic radiotherapy\n* No prior treatment with capecitabine and/or lapatinib ditosylate\n* No prior resection of the stomach or small bowel\n* No concurrent systemic treatment or radiation therapy for breast cancer (except corticosteroid, bisphosphonates, or mannitol)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}